Nine Stocks Poised to Defy 'Sell in May' as Market Hits New Highs

The traditional market adage "Sell in May and Go Away" faces a compelling challenge in 2026. With the S&P 500 and NASDAQ opening May at record highs fueled by an exceptional earnings season, selective investors are finding compelling reasons to stay invested rather than retreat to the sidelines. An impressive 84% of companies beat earnings expectations during the recent earnings cycle, coupled with robust 27% earnings growth, suggests that market strength may have more runway despite persistent headwinds from geopolitical tensions and elevated valuations.

While the "Sell in May" strategy has historically guided investors toward safer positions during the seasonally weaker summer months, 2026's market dynamics tell a different story. The combination of record indices and strong corporate performance creates an environment where fundamentally sound companies with solid analyst support could deliver significant returns even as seasonal patterns typically cool investor appetite.

Strong Earnings Momentum Defies Seasonal Skepticism

The numbers driving this year's market resilience are striking. The earnings season that set the stage for May's record-breaking indices demonstrated broad-based strength across corporate America:

• 84% of companies exceeded earnings expectations during the latest reporting cycle
• 27% earnings growth year-over-year, indicating substantial bottom-line expansion
• S&P 500 and NASDAQ at record highs entering the seasonal weakness period
• Earnings beat rate far exceeding historical averages, suggesting companies are delivering tangible value

This performance stands in sharp contrast to typical May environments, where earnings momentum often begins to fade and investors become increasingly cautious about summer volatility. The strength of recent results provides a foundational argument for investors to reconsider the blanket "Sell in May" approach.

Among the highlighted opportunities, DexCom and ResMed exemplify the type of fundamentally strong companies attracting investor attention. Both companies demonstrated robust results in their most recent quarterly reports, with DexCom showing strong Q1 performance and ResMed delivering impressive Q3 results. Each has generated meaningful analyst support, suggesting market professionals see additional upside potential beyond current valuations.

Market Context: Navigating Risk Amid Record Valuations

The broader market context reveals a landscape of both opportunity and caution. While the 84% earnings beat rate and 27% earnings growth provide compelling fundamental support for equity positions, several risk factors warrant careful consideration from investors seeking to participate in potential May-through-summer gains.

Global tensions represent a material headwind, with geopolitical uncertainties potentially creating volatility that could test investor conviction during traditionally weaker trading months. Additionally, stretched valuations across many market segments suggest that not all equities offer the same margin of safety. This environment demands the selective approach highlighted in current investment recommendations—favoring companies with demonstrable fundamental strength and analyst conviction.

The competitive landscape has evolved significantly, with healthcare and technology sectors showing particular resilience. DexCom operates in the continuous glucose monitoring space, where secular growth trends remain intact despite competitive pressures. ResMed, positioned in cloud-based software and connected care solutions for out-of-hospital care, benefits from structural tailwinds in healthcare digitization and aging population trends.

Historically, the "Sell in May" pattern reflected seasonal liquidity patterns and summer trading volume declines. However, in markets characterized by strong fundamentals and broad earnings beats, this seasonal framework becomes less reliable. Professional investors increasingly recognize that rigid adherence to calendar-based strategies can result in missing significant return opportunities when underlying business conditions remain robust.

Investor Implications: A Selective Approach to May Seasonality

For equity investors navigating 2026's unique market environment, several implications emerge from the current setup:

Fundamental strength matters more than ever. With earnings beats running at 84% and growth at 27%, the ability to identify companies with sustainable competitive advantages becomes paramount. The dispersion of results suggests that not all businesses are equally positioned for success, creating meaningful return differentiation.

Valuation considerations remain critical. While earnings growth is impressive, stretched valuations create vulnerability to sentiment shifts. Investors should focus on companies where growth rates justify current price levels, providing a cushion against multiple compression.

Analyst support signals conviction. The stocks highlighted—$DXCM (DexCom) and $RMD (ResMed)—possess analyst backing that suggests professional investors see meaningful upside. This consensus view, combined with strong recent results, provides additional validation for selective positions.

Geopolitical hedging warrants consideration. Global tensions could create volatility that tests investor confidence during historically weak trading periods. Diversification and position sizing become increasingly important risk management tools.

Sector selection matters. Healthcare and technology stocks showing strong earnings and analyst support may outperform more economically sensitive sectors if geopolitical tensions escalate or economic growth slows.

The nine stocks identified as potential "Sell in May" defiers share common characteristics: strong recent earnings results, analyst consensus supporting further gains, exposure to secular growth themes, and valuations that offer meaningful upside potential. Rather than blanket market exposure, this approach emphasizes security selection within a generally positive market environment.

Looking Ahead: May's Opportunity Set

As 2026 progresses into its seasonally challenging months, the traditional "Sell in May" framework appears increasingly obsolete in the face of record market highs, 84% earnings beat rates, and 27% earnings growth. However, this does not constitute an argument for undifferentiated market participation. Instead, it suggests that disciplined investors with conviction in specific companies' fundamentals may find the May-through-August period particularly rewarding.

The market's record valuations combined with solid earnings momentum creates a bifurcated opportunity set. Investors who identify and concentrate on fundamentally strong companies with analyst support—exemplified by names like DexCom and ResMed—could potentially defy seasonal weakness. Conversely, those holding economically sensitive or richly valued securities without clear earnings justification may experience typical May-through-summer pressure.

The decision to "Sell in May" in 2026 should depend less on the calendar and more on company-specific fundamentals, valuation discipline, and conviction in earnings sustainability. For investors willing to do that work, the market's strength entering May presents a genuine opportunity to participate in continued gains rather than retreat to the sidelines.